TRANSCATHETER VALVE THERAPIES: A DECADE OF CARDIOTHORACIC INNOVATION AND FUTURE PROMISE juliopaza98@gmail.com

462-04

TRANSCATHETER VALVE THERAPIES: A DECADE OF CARDIOTHORACIC INNOVATION AND FUTURE PROMISE

8

Mexico

Oral or Poster

Transcatheter aortic and mitral valve therapies (TAVR/TMVR) have redefined cardiothoracic surgery, offering less invasive alternatives to open procedures. This narrative review synthesizes a decade of evidence to explore their long-term impact and evolving role in personalized cardiac care.

We reviewed literature from 2015–2024, including PARTNER trial data, STS/ACC TVT Registry reports, and TMVR studies. Focus areas encompassed patient selection, procedural success, valve durability, and quality of life (QoL) outcomes. Data were sourced from peer-reviewed journals and cardiothoracic conference proceedings.

PARTNER 3 trial data (2020–2024) show TAVR achieves 5-year mortality equivalence to surgical aortic valve replacement in low-risk patients (8.5% vs. 9.2%, p=0.41), with shorter recovery (3 vs. 7 days hospitalization). TMVR, per COAPT trial follow-ups, reduces heart failure readmissions by 30% in functional mitral regurgitation (p<0.01). QoL improves significantly post-TAVR, with KCCQ scores rising by 22 points at 1 year. However, valve durability remains a concern, with 10% of TAVR valves showing degeneration by 8 years. Patient selection, particularly frailty and comorbidity assessment, critically influences outcomes.

Transcatheter valve therapies have revolutionized cardiothoracic surgery, delivering comparable outcomes with reduced invasiveness across diverse populations. Challenges include ensuring valve longevity and refining selection criteria. Innovations like bioresorbable valves and AI-driven risk stratification herald a future of precision-driven care, solidifying transcatheter approaches as cornerstones of modern cardiothoracic practice.